RxDoctor Payments Data

Amanda Allen, PA

Physician Assistant · Tustin, CANPI 1083477152

Payments from drug & device makers

$1,810in general payments, 2019–2025

Across 34 payments — averaging $53.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Medtronic$155
  • AbbVie$144
  • Sumitomo Pharma America, Inc.$43
  • Merz North America, Inc.$32
  • Myriad Genetic Laboratories, Inc.$26
  • plus $26 from 1 others

What the payments were for

  • Travel & lodging$67938%
  • Food & beverage$1,13162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,810 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$50,840
Medicare patients
273
Services billed
1,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron35$33,233
MyrbetriqMirabegron30$22,849
Estradiol147$9,727
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav213$9,399
Fosfomycin Tromethamine32$8,786
NitrofurantoinNitrofurantoin Macrocrystal110$5,353
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst224$2,413
Tamsulosin Hcl104$1,668
Cefpodoxime Proxetil20$1,593
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim108$1,315
Finasteride53$796
Cephalexin24$676
Cefdinir39$649
Oxybutynin Chloride ErOxybutynin Chloride31$492
Ciprofloxacin Hcl64$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$43$33,23335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →